GLP-1 administration test for assessing the glucose metabolism and predictive efficacy of the incretin based treatment

GLP-1 administration test for assessing the glucose metabolism and predictive efficacy of the incretin based treatment - GLP-1 administration test

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010067

Enrollment

Registered

2013-04-01

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

GLP-1 saline

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diabetes mellitu type 2 without using incretin based drugs.

Exclusion criteria

Exclusion criteria: Patient with severe complication (proliferative retinopathy, serum cleatinine > 2.0 mg/dL, cerebrovascular disease, and/or ischemic heart diseases), severe liver dysfunction and/or dementia.

Design outcomes

Primary

Measure	Time frame
1. Insulin secretion in GLP-1 administration compared to saline administration using meal tolerance test. 2. The relationship between the result of GLP-1 administration test and the changes of HbA1c after incretin based treatment.	—

Countries

Japan

Contacts

Public ContactHiroaki Ueno

Miyazaki university, fuculty of medicine Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine

intron@med.miyazaki-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026